News

In the past week, Tempus AI, Inc. reported second-quarter 2026 results showing revenue of US$382.49 million and a swing from a net loss of US$42.84 million a year ago to net income of US$5.64 million, while also raising its full-year 2026 revenue outlook to between US$1.60 billion and US$1.61 billion. Alongside this performance, Tempus AI advanced its oncology and data ambitions through the planned acquisition of Personalis and highlighted growing diagnostics volume and new data...

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intelligence offerings, and expected reimbursement benefits from newly approved diagnostic products. Reve

IPO Edge hosted a fireside chat on July 28 from the floor of the New York Stock Exchange with Don Duffy, President and Chairman of the Board of ICR […]

While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Tempus AI is set to report its Q2 results today. Investors will be watching.

TEM heads into Q2 earnings with 21.3% expected revenue growth, strong diagnostics demand and AI deals, but near-term margin pressure remains.

ARK Invest bought about 160,000 shares of Tesla stock on Thursday, as shares of the EV maker plunged almost 15%.

Tempus AI (TEM) spent three years selling someone else's cancer test. On Monday, July 20, it decided to just buy the whole thing. The AI diagnostics company agreed to acquire Personalis (PSNL) in a deal valued at $1.5 billion. The move hands Tempus full control of a test that spots cancer ...

Tempus AI’s Personalis deal puts acquisition price and growth bets in focus Tempus AI (TEM) has moved to acquire cancer testing company Personalis in a roughly $1.5 billion all stock deal, immediately putting the spotlight on valuation, integration risk, and long term growth assumptions. The agreement would fold Personalis’ minimal residual disease, or MRD, testing into Tempus AI’s precision oncology and data platform. The combined business would target a cancer monitoring market estimated at...

The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test

Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.

Tempus AI (NASDAQ:TEM) executives said the company’s planned acquisition of Personalis is intended to strengthen its position in minimal residual disease, or MRD, testing, while expanding its biopharma data and profiling capabilities. On a call with analysts, Tempus said it agreed to acquire all ou

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.

Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a...

Tempus AI is acquiring Personalis to accelerate the development and commercialization of cancer-monitoring solutions.

Tempus AI (TEM) has agreed to acquire Personalis (PSNL) in a deal with a total enterprise value of $

Personalis stock popped Friday on a rumor Merck and at least two other suitors are trying to buy the small genomics company.

Editor’s Note: This story has been updated to correct details related to Intel (INTC). When it comes to tracking the trading activity of members of Congress, former Speaker of the House Nancy Pelosi (D-Calif.) has been among the most followed....

Tempus AI, Inc. (NASDAQ:TEM) is one of the 10 Best Under-the-Radar Stocks to Invest In. On July 1, Freedom Capital initiated coverage of Tempus AI, Inc. (NASDAQ:TEM) with a Hold rating. The firm gave a $59 price target on the shares. In an investor note, the firm noted that healthcare AI remains one of the […]

Tempus AI Inc. (NASDAQ:TEM) is one of the top 10 hidden AI stocks to buy. On May 31, Tempus AI launched the next generation of Lens, an agentic AI platform designed to accelerate oncology drug development. By integrating Tempus’ massive library of longitudinal real-world data, oncology foundation models, and computational infrastructure, the platform provides an […]

Tempus AI Inc. (NASDAQ:TEM) is one of BlackRock’s 30 most important AI stocks right now. BlackRock holds a 5.14% stake in the company, with 8.97 million shares as of March 31, 2026. However, Cathie Wood’s ARK Investment Management controls a slightly higher stake at 5.51%, making BlackRock the second-largest institutional holder. Tempus became an investor […]

By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers. NavDx is the first and only Medicare-covered test for HPV-driven head and neck and anal cancer molecular […] The post CareDx Acquires Naveris, Extends Leadership into High-Growth Specialty Oncology appeared first on ExecEdge.

Tempus AI recently announced a research collaboration with Angiosarcoma Awareness, Inc. to apply its approximately 600 de-identified, molecularly sequenced angiosarcoma records and analytical resources to deepen understanding of this rare and aggressive cancer. This partnership creates one of the largest known angiosarcoma molecular datasets, offering researchers a more comprehensive view of disease biology and potential therapeutic opportunities that are hard to see in smaller, fragmented...

Freedom Capital initiated Tempus AI with a Hold rating and $59 price target, saying valuation looks “about right.

The biggest long-term winners of the AI revolution may be the companies supplying the compute, power, cooling, deployment, and data infrastructure that every AI model depends on.

Cathie Wood Loads Up on AI Winners as She Cuts Roku and China Exposure

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

Congresswoman and former Speaker of the House Nancy Pelosi (D-Calif.) is one of the most followed members of Congress when it comes to her disclosed stock and options trades. Here’s a look at the trades disclosed by Pelosi since the...

Tempus AI Inc. (NASDAQ:TEM) is one of the 10 worst artificial intelligence stocks under $30 according to short sellers. During the first week of June, Tempus AI Inc. (NASDAQ:TEM) shared the impending clinical availability for its advanced sequencing test, xH. It detects oncologic targets within bone marrow and peripheral blood samples, based on whole-genome sequencing […]

We just covered the 10 Stocks That Will 10X According to Social Media. Tempus AI (NASDAQ:TEM) ranks #7 (see 5 Stocks That Will 10X According to Social Media). Number of Hedge Fund Investors: 33 Tempus AI (NASDAQ:TEM) runs cancer diagnostic tests and sells the resulting data and AI tools to pharmaceutical companies and research institutions. […]